Evidence map›Paper›PMID 42092615›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

Atomic layering thermostable antigen and adjuvant (ALTA®) provides unique, controlled antigen release to improve immune response to vaccination.

Keith A Strand, Heather D'Angelo, Ashley M Olson, Isabella R Walters, Emma M Snyder, Alyssa M Ritter, Emily Hite, Yalini H Wijesundara, Annie B Caplan, Daria L Ivanova and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Keith A StrandVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Heather D'AngeloVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Ashley M OlsonVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Isabella R WaltersVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Emma M SnyderVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Alyssa M RitterVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Emily HiteVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Yalini H WijesundaraVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Annie B CaplanVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Daria L IvanovaVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Isabella AllenVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Yu HanVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Lorena R AntunezVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Antu K DeyVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Bryan L SteadmanVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA.
Sky W BrubakerVitriVax, Inc., 5500 Central Avenue, Boulder, CO 80301, USA. Electronic address: sbrubaker@vitrivaxbio.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prophylactic vaccines commonly require a multi-dose regimen to achieve robust, durable protection against a specific pathogen. However, poor patient adherence to these regimens reduces overall protection and highlights the need to develop single-shot vaccines without compromising efficacy. Utilizing atomic-layer deposition (ALD) to coat spray-dried, thermostable, antigen-containing microparticles with alumina (Al

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineAIDS VaccinesAluminum OxideAntigensenv Gene Products, Human Immunodeficiency VirusOvalbuminAnimalsDelayed-Action PreparationsDrug LiberationFemaleImmunity, HumoralMiceMice, Inbred BALB CVaccinationAdjuvants, ImmunologicAdjuvants, VaccineAIDS VaccinesAluminum OxideAntigensDelayed-Action Preparationsenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1OvalbuminALTA®Antibody responseHIV-1 vaccineMicroparticlesN332-GT5 gp140Sustained releaseThermostabilityVaccines

Identifiers

PMID42092615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.